# US 2025/0367255 A1 · Enhancement Of CD47 Blockade Therapy With Anti-VEGF Agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367255 A1
- Document ID: US20250367255A1
- Status: Published application
- Kind: A1
- Application number: 18/708,093
- Filed: 2022-11-01
- Published: 2025-12-04
- Earliest claimed: 2021-11-08
- Assignees: Pfizer Inc.
- Applicants: Pfizer Inc.
- Inventors: Gloria Hoi Ying LIN; Robert Adam UGER; Mark Michael WONG
- Web page: https://patentgrep.com/patent/US20250367255A1

## CPC

- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- C07K 14/70503: {Immunoglobulin superfamily}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/53: Hinge
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Various forms of cancer and other diseases are treated using a medicinal combination of a SIRPαFc to block binding with CD47, and an anti-VEGF agent such as humanized antibody bevacizumab to control vascularization.

## Claims

### Claim 1

A method for treating a subject presenting with CD47+ disease cells, comprising administering to the subject a treatment-effective combination comprising (1) a CD47-binding form of SIRPαFc, and (2) an anti-VEGF agent.

### Claim at position 2

2-7. (canceled)

### Claim 8 (depends on 1)

The method according to claim 1, wherein the anti-VEGF agent is an anti-VEGF antibody or an anti-VEGF receptor antibody.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the anti-VEGF agent is an anti-VEGF antibody.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the anti-VEGF agent is bevacizumab or a VEGF-binding fragment or variant of bevacizumab.

### Claim at position 6

11-12. (canceled)

### Claim 13 (depends on 8)

The method according to claim 8, wherein the anti-VEGF agent is an anti-VEGF receptor antibody.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the anti-VEGF agent is an anti-VEGFR-2 antibody.

### Claim at position 9

15-16. (canceled)

### Claim 17 (depends on 1)

The method according to claim 1, wherein the SIRPαFc comprises the IgV region of human SIRPα variant 2.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the SIRPαFc fusion protein comprises the amino acid sequence of SEQ ID NO: 3.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the SIRPαFc fusion protein comprising comprises the amino acid sequence of SEQ ID NO: 8.

### Claim 20 (depends on 1)

The method according to any claim 1, wherein the CD47+ disease cells comprise CD47+ cancer cells.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the CD47+ cancer cells are blood cancer cells or solid tumour cells.

### Claim 22 (depends on 20)

The method according to claim 20, wherein the CD47+ cancer cells comprise blood cancer cells.

### Claim at position 16

23-28. (canceled)

### Claim 29 (depends on 21)

The method according to claim 21, wherein the cancer cells comprise solid tumour cells.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the solid tumour cancer cells comprise breast cancer cells, lung cancer cells, or ovarian cancer cells.

### Claim at position 19

31-32. (canceled)

### Claim 33 (depends on 29)

The method according to claim 29, wherein the solid tumour CD47+ cancer cells are selected from colorectal, renal, hepatocellular carcinoma and glioblastoma cells.

### Claim 34

(canceled)

### Claim 35 (depends on 1)

A combination of anti-cancer agents, comprising an amount of a CD47 binding form of SIRPαFc, and an amount of bevacizumab effective, in combination, to deplete CD47+ cancer cells, together with instructions teaching the use thereof according to claim 1.

### Claim 36 (depends on 35)

The use of the combination according to claim 35, for the treatment of a subject presenting with CD47+ disease cells.

### Claim at position 24

37-40. (canceled)

### Claim 41 (depends on 36)

The use according to claim 36, wherein the CD47-blocking from of SIRPαFc comprises SEQ ID NO: 3.

### Claim 42 (depends on 36)

The use according to claim 36, wherein the CD47-blocking from of SIRPαFc comprises SEQ ID NO: 8.

### Claim 43

comprising unit dose formulations of a CD47-binding form of SIRPαFc, and an anti-VEGF agent.

### Claim 44 (depends on 43)

The kit according to claim 43, wherein the CD47-binding form of SIRPαFc, and an anti-VEGF agent are packaged together but not in admixture.
